The Phase 1 driving simulation data for GlyphAllo is a modest positive derisking event, but the stock's next major catalyst is the Phase 2b BUOY-1 topline readout in 1H 2027. Monitor enrollment updates and any early efficacy signals from the ongoing Phase 2a GlyphAgo trial.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 2 $20.01entry
- T+1 · yesterday +0.95%α +0.65% · $20.20
- T+2 · todayOpen
- T+5 · in 5d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seaport Therapeutics reported a Q3 2026 net loss of $26.4 million, wider than the $22.5 million loss in Q3 2025, and in line with consensus expectations for a pre-revenue clinical-stage biotech. The key positive was positive topline data from the Phase 1 driving simulation trial for GlyphAllo, showing no next-morning driving impairment, which de-risks the program. Cash of $403.8 million funds operations into 2029 through multiple data readouts.
Key Financial Metrics
Key Facts
- Net loss of $26.4 million for Q3 2026 vs $22.5 million in Q3 2025.
- Cash, cash equivalents, and investments of $403.8 million as of September 30, 2026.
- Positive topline data from Phase 1 driving simulation trial of GlyphAllo: no next-morning driving impairment vs placebo.
- First patient dosed in Phase 2a trial of GlyphAgo in GAD and sleep disturbance.
- Enrollment on track in Phase 2b BUOY-1 trial of GlyphAllo in MDD; topline data expected in 1H 2027.
- R&D expenses were $23.9 million vs $20.5 million in Q3 2025.
- G&A expenses were $6.5 million vs $5.0 million in Q3 2025.
Financial Impact
Net loss of $26.4 million, cash burn of $23.5 million from $427.3 million at June 30 to $403.8 million at September 30, 2026.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; relies on successful trial outcomes.
- Phase 2b BUOY-1 trial failure would be a material negative for the stock.
- Cash runway into 2029 but may need additional financing if trials are delayed or expanded.
- Liver safety concerns for GlyphAgo (agomelatine-based) despite Phase 1 data showing no liver enzyme elevations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-442625 |
| Document: sptx-20261102.htm | 0001193125-26-442625 |
| Document: 0001193125-26-442625-index-headers.html | 0001193125-26-442625 |
| Document: 0001193125-26-442625-index.html | 0001193125-26-442625 |
| Document: 0001193125-26-442625.txt | 0001193125-26-442625 |
| 8-K Data (Synthetic) | 0001193125-26-442625 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | Insider Buy | $20.01 | awaiting T+60 | awaiting T+60 | $20.82 (+4.05%) |
Nov 2, 2026 2d ago | 8-K | $20.01 | awaiting T+60 | awaiting T+60 | $20.82 (+4.05%) |
Aug 3, 2026 13w ago | 8-K | $20.65 $21.51 | ▲ +4.16% | ▲ +2.38% | $20.82 (+0.82%) |
Jun 8, 2026 21w ago | 8-K | $16.20 $23.61 | ▲ +45.74% | ▲ +42.69% | $20.82 (+28.52%) |
May 6, 2026 25w ago | 3 | $15.50 $20.65 | ▲ +33.23% | ▲ +29.39% | $20.82 (+34.32%) |
May 1, 2026 26w ago | 424B4 | $17.00 $19.74 | ▲ +16.12% | ▲ +14.26% | $20.82 (+22.47%) |
Apr 30, 2026 26w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $20.82 (+4.94%) |
Apr 30, 2026 26w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $20.82 (+4.94%) |
Apr 30, 2026 26w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $20.82 (+4.94%) |
Apr 30, 2026 26w ago | 3 | $19.84 $19.90 | ▲ +0.30% | ▼ −2.77% | $20.82 (+4.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers